| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 11/17/2005 | US20050255131 Clindamycin compositions and delivery system therefor |
| 11/17/2005 | US20050255130 Retinoid solutions and formulations made therefrom |
| 11/17/2005 | US20050255124 HCV E1E2 vaccine compositions |
| 11/17/2005 | US20050255119 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives |
| 11/17/2005 | US20050255091 Hydrogels for biomedical applications |
| 11/17/2005 | US20050255063 Candy cosmetics |
| 11/17/2005 | US20050255051 Formulation for inhalation |
| 11/17/2005 | US20050255049 Formoterol and mometasone aerosol formulations |
| 11/17/2005 | US20050255048 Sprayable formulations for the treatment of acute inflammatory skin conditions |
| 11/17/2005 | US20050255039 Gel injection treatment of breast, fibroids & endometrial ablation |
| 11/17/2005 | DE102004019916A1 Gegen Missbrauch gesichertes wirkstoffhaltiges Pflaster Against abuse secured medicated plaster |
| 11/17/2005 | CA2821167A1 Drug delivery liposomes containing anionic polyols or anionic sugars |
| 11/17/2005 | CA2774146A1 Steroid intraocular implants having an extended sustained release for a period of greater than 2 months |
| 11/17/2005 | CA2759777A1 Method of producing foamed cleanser with suspended particles, and a dispenser therefor |
| 11/17/2005 | CA2566433A1 Therapeutic agent for bh4-responsive hyperphenylalaninemia |
| 11/17/2005 | CA2566153A1 Foamed cleanser with suspended particles, a method of producing same and a dispenser therefore |
| 11/17/2005 | CA2566098A1 Therapeutic agent for keratoconjunctival disorder |
| 11/17/2005 | CA2566007A1 Drug delivery liposomes containing anionic polyols or anionic sugars |
| 11/17/2005 | CA2565667A1 Directly compressible tricalcium phosphate |
| 11/17/2005 | CA2565459A1 Anti-excitotoxic sustained release intraocular implants and related methods |
| 11/17/2005 | CA2565393A1 Remote control release of material encapsulated in polyelectrolyte multilayer microcapsules |
| 11/17/2005 | CA2565363A1 Use of targeted oxidative therapeutic formulation in treatment of diabetes and obesity |
| 11/17/2005 | CA2565295A1 Steroid intraocular implants having an extended sustained release for a period of greater than 2 months |
| 11/17/2005 | CA2565285A1 Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing |
| 11/17/2005 | CA2565236A1 Particles for the delivery of active agents |
| 11/17/2005 | CA2565221A1 Biodegradable intravitreal tyrosine kinase inhibitors implants |
| 11/17/2005 | CA2565183A1 Topical preparation containing ambroxol |
| 11/17/2005 | CA2565083A1 Novel pharmaceutical dosage form and manufacturing process |
| 11/17/2005 | CA2564886A1 Nutritional composition for enhancing lean muscle stimulus, growth, strength and recovery, creating and prolonging intense muscle pumps, supporting endurance, strength, performance, size and stamina, providing a transducer effect for nitric oxide, increasing nutrient delivery and/or promoting increased vascular response in an individual |
| 11/17/2005 | CA2564750A1 Controlled release metformin compositions |
| 11/17/2005 | CA2564634A1 Permeation enhancing compositions for anticholinergic agents |
| 11/17/2005 | CA2563086A1 Naltrexone long acting formulations and methods of use |
| 11/17/2005 | CA2562287A1 Sustained-release oral molsidomine composition for treating atherosclerosis |
| 11/16/2005 | EP1595884A2 Salt of sulfonic acid containing clopidogrel and use thereof for the production of pharmaceutical formulations |
| 11/16/2005 | EP1595549A1 Dispersant for sustained release preparations |
| 11/16/2005 | EP1595538A2 Modified release tamsulosin tablets |
| 11/16/2005 | EP1595537A1 Buccal cavity treatment composition and corresponding uses thereof |
| 11/16/2005 | EP1595535A2 Delivery device containing venlafaxine and memantine and use method thereof |
| 11/16/2005 | EP1595534A1 Gel composition comprising charged polymers |
| 11/16/2005 | EP1595533A1 Tablet quickly melting in oral cavity |
| 11/16/2005 | EP1595532A2 Sustained release of peptides from pharmaceutical compositions |
| 11/16/2005 | EP1595531A1 Stable pharmaceutical solution formulations for pressurized metered dose inhalers |
| 11/16/2005 | EP1595529A1 Cosmetically or dermatologically impregnated wipes |
| 11/16/2005 | EP1594977A2 Reversible attachment of a membrane active polymer to a polynucleotide |
| 11/16/2005 | EP1594668A1 Pelletizing yew biomass for extraction of taxanes and other natural products |
| 11/16/2005 | EP1594603A1 High temperature high pressure capsule for processing materials in supercritical fluids |
| 11/16/2005 | EP1594552A2 Topical delivery of cosmetic agents |
| 11/16/2005 | EP1594547A2 Chitosan-microparticles for ifn gene delivery |
| 11/16/2005 | EP1594546A1 Salicylic acid derivative as efficacy enhancer and method |
| 11/16/2005 | EP1594545A2 Pharmaceutical composition for transdermal or transmucosal administration |
| 11/16/2005 | EP1594544A2 Oral compositions of fenretinide having increased bioavailability and methods of using the same |
| 11/16/2005 | EP1594540A1 New pharmaceutical compositions based on anticholinergics and anti-tnf antibodies |
| 11/16/2005 | EP1594538A2 Composition to be administered to a living being and method for marking agents |
| 11/16/2005 | EP1594531A1 Storage-stable and bio-stable formulations of ace inhibitors, and methods for preparation thereof |
| 11/16/2005 | EP1594528A1 New pharmaceutical compositions based on anticholinergics and soluble tnf receptor fusion proteins |
| 11/16/2005 | EP1594515A2 Drug formulation and delivery using crystalline methylated cyclodextrins |
| 11/16/2005 | EP1594510A2 Method and kit for reducing the symptoms of peripheral vascular disease |
| 11/16/2005 | EP1594500A1 Treatment of bacterial diseases of the respiratory organs by locally applying fluoroquinolones |
| 11/16/2005 | EP1594499A1 Dosage forms containing a proton pump inhibitor, a nsaid, and a buffer |
| 11/16/2005 | EP1594488A2 Stabilized pharmaceutical compositions of safingol and methods of using the same |
| 11/16/2005 | EP1594484A2 Pharmaceutical patch |
| 11/16/2005 | EP1594483A1 Uv stable transdermal therapeutic plaster |
| 11/16/2005 | EP1594482A1 Intravenous nanoparticles for targeting drug delivery and sustained drug release |
| 11/16/2005 | EP1594480A1 Method to treat chronic heart failure and/or elevated cholesterol levels |
| 11/16/2005 | EP1594479A1 Stable oral benzimidazole compositions and processes for their preparation |
| 11/16/2005 | EP1594478A1 Chewing gum in the form of multi-layer tablets |
| 11/16/2005 | EP1594477A2 Active drug delivery in the gastrointestinal tract |
| 11/16/2005 | EP1594476A2 Method and apparatus for treating bodily tissues with medicinal substance |
| 11/16/2005 | EP1594475A1 Self-expanding device for the gastrointestinal or urogenital area |
| 11/16/2005 | EP1594474A2 Coated particles and pharmaceutical dosage forms |
| 11/16/2005 | EP1594473A2 Composition and method for treating age-related disorders |
| 11/16/2005 | EP1594472A1 Drug delivery from embolic agents |
| 11/16/2005 | EP1594471A1 Dexamethasone-containing formulations for oral administration as well as the process for manufacturing required therefor |
| 11/16/2005 | EP1594470A2 Rapid absorption selective 5-ht agonist formulations |
| 11/16/2005 | EP1594469A1 Peptidic nanoparticles as drug delivery and antigen display systems |
| 11/16/2005 | EP1594468A2 Process for preparing a solid dispersion pharmaceutical product |
| 11/16/2005 | EP1594467A1 Abuse-deterrent pharmaceutical compositions of opioids and other drugs |
| 11/16/2005 | EP1594466A1 Virosome-like-particles |
| 11/16/2005 | EP1594465A2 Compositions comprising a plurality of particles or agglomerates having a defined particle size |
| 11/16/2005 | EP1594464A2 Compositions comprising a defined polysaccharide component |
| 11/16/2005 | EP1594463A2 Compositions comprising a polysaccharide component and one or more coating layers |
| 11/16/2005 | EP1594462A1 Surgical implant compprising an anabolic and a corticosteroid |
| 11/16/2005 | EP1594461A2 Anti-microbial nonwoven wipe |
| 11/16/2005 | EP1594460A2 Sustained-release tramadol formulations with 24-hour efficacy |
| 11/16/2005 | EP1594459A2 Drug delivery from rapid gelling polymer composition |
| 11/16/2005 | EP1594434A2 Parenteral formulations of peptides for the treatment of systemic lupus erythematosus |
| 11/16/2005 | EP1594371A1 Compositions containing creatine, creatinine and a methyl xanthine |
| 11/16/2005 | EP1379138B1 Liquid formulations for dermal application in treatment of parasitic insects in animals |
| 11/16/2005 | EP1368419B1 A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge |
| 11/16/2005 | EP1363608B1 Formulations comprising ibuprofen and diphenhydramine and the use thereof for the treatment of sleep disturbances |
| 11/16/2005 | EP1345611A4 An antibiotic/analgesic formulation and a method of making this formulation |
| 11/16/2005 | EP1341522B1 Microparticles with an improved release profile and method for the production thereof |
| 11/16/2005 | EP1305378B1 Medical contact adhesive comprising a two phase adhesive matrix of polyacrylates and polyamine salts |
| 11/16/2005 | EP1299085B1 Improved liposomal camptothecins and uses thereof |
| 11/16/2005 | EP1299084B1 Liposomal antineoplastic drugs and uses thereof |
| 11/16/2005 | EP1292386B1 Novel microcapsules |
| 11/16/2005 | EP1289517B1 Pharmaceutical compositions comprising cannabidiol derivatives |
| 11/16/2005 | EP1274459B1 Sustained release formulations comprising growth hormone |
| 11/16/2005 | EP1237543B1 Effervescent histamine h2 antagonist composition |
| 11/16/2005 | EP1220663B1 Superficial therapeutic system for topically applying acetylsalicylic acid, for the treatment of acne-related diseases |